Table 2.
Baseline Characteristics of PLWH
| Characteristics | Patients (n=47) |
|---|---|
| Time of HIV diagnosis, mean (range), years | 2.5 (0.5–11) |
| HIV viral load, median (range), copies/mL | 20 (20–163,827) |
| CD4+ T cell counts, mean (range), cells/uL | 474 (145–926) |
| CD8+T cell counts, median (IQR), cells/uL | 804 (560–1096) |
| CD4/CD8 ratio, median (IQR) | 0.58 (0.43–0.79) |
| CD4+ T cell counts before vaccination, mean (range), cells/uL | 433 (124–801) |
| CD8+ T cell counts before vaccination, median (IQR), cells/uL | 909 (701–1408) |
| CD4/CD8 ratio before vaccination, median (IQR) | 0.46 (0.30–0.73) |
| ART use, n (%) | |
| 2NRTIs+1NNRTIs | 38 (80.9) |
| 2NRTIs+1INSTIs | 2 (4.3) |
| 2NRTIs+1PIS | 1 (2.1) |
| Others | 6 (12.80) |
| Comorbidities, n (%) | |
| Syphilis | 6 (12.80) |
| Diabetes | 2 (4.30) |
| Cardiovascular disease | 1 (2.10) |
| Hypertension | 0 (0.00) |
Abbreviations: NRTIs, nucleoside reverse transcriptase inhibitors; NNRTIs, nonnucleoside reverse transcriptase inhibitors; INSTIs, integrase inhibitors; PIs, protease inhibitors.